Vall d'Hebron Institute of Oncology (VHIO)
Anna Palazón Zabala is a Clinical Research Manager at Vall d'Hebron Institute of Oncology (VHIO) since July 2021, overseeing CRA personnel and managing oncology clinical trials from Phase I to III, involving tasks such as clinical project management, quality assurance, and medical writing. Previously, Anna served as a Clinical Study Coordinator in oncology at IMIM from February 2018 to July 2021, coordinating clinical trials and ensuring compliance with safety reporting and data management protocols. Earlier experience includes roles as a Clinical Research Associate at IMIM, where Anna contributed to trial monitoring and quality assurance, and as a Veterinary Physician in various veterinary clinics, focusing on clinical care and minor surgeries. Academic credentials include a Degree in Veterinary Medicine from Universitat Autònoma de Barcelona and multiple master's degrees and postgraduate courses in clinical research, industrial pharmacy, and laboratory animal science.
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.